Navigation Links
Trial aims to advance prenatal diagnosis of genetic defects

NEW YORK (August 21, 2013) Reproductive genetics researchers at Columbia University Medical Center (CUMC) are leading a multicenter prospective clinical study investigating the effects of chromosomal abnormalities (duplicative or missing material) found prenatally through microarray analysis. The goal of the study is to gain further information on genetic variances previously not well reported in the medical literature and share it with parents during pregnancy.

Led by principal investigator Ronald J. Wapner, MD, professor and vice chair for research at CUMC's Department of Obstetrics and Gynecology and director of reproductive genetics at NewYork-Presbyterian Hospital/Columbia, the research is the next phase of a project to advance clinicians' ability to diagnose in utero conditions such as developmental delays, structural abnormalities, and treatable or life-threatening diseases.

"Parents of children found to have a genetic variance want a better understanding of what it means. Our goal is to give them as much information and support as possiblefrom detailed genetic counseling to ways to connect with other people expecting children with the same variance," said Dr. Wapner.

In December 2012, Dr. Wapner and colleagues published in the New England Journal of Medicine (NEJM) findings of a trial involving 4,400 patients at 29 centers nationwide. That study showed that microarray analysis of a fetus's DNA gave significantly more clinically relevant information than the standard method of analysis, known as karyotypinga visual analysis of the fetus's chromosomes. [Click here for a news release about that study.]

In the current studywhich has ongoing clinical recruitmentdata on babies included in the NEJM article will be augmented by data on patients recruited by 10 major prenatal diagnostic centers around the country that offer microarray to all their patients. Each center aims to recruit 1,000 patients. Of the anticipated 10,000 or so microarray analyses, the researchers aim to follow 300600 children born with genetic variances, for at least three years. (See below for more about microarray.)

"While the majority of abnormalities found with microarray are associated with known conditions, in many cases the full implications of findings are not well understood, and about 1.5 percent are unidentified. The goal is to fill in these knowledge gaps," said Dr. Wapner. "Ours is the only study of its kind that is identifying genetic variances in utero and following the kids over time to see how the abnormalities present and to gather as much clinical information about them as possible, such as the severity of problems and life expectancy."

"When we counsel parents now, we can give them only limited information, drawn from what we know about children who have undergone genetic testing. But these children often represent the severe end of the spectrum," said Dr. Wapner. "There might be people who, because they had no symptoms, were never identified as having a variance, limiting the prognostic information we are able to give parents."

NewYork-Presbyterian/Columbia is the primary recruitment center. The other centers participating in the study are: the Center for Fetal Medicine, Northwestern University, Cedars Sinai Medical Center, San Francisco Perinatal, Carnegie Hill Imaging, Montefiore Medical Center, Mount Sinai Medical Center, Lenox Hill, and North Shore LIJ.

A majority of the labs in the country that do prenatal microarray have agreed to refer patients to the website, where they will be able to self-enroll in the study. "We hope to capture almost all the available microarray data," said Dr. Wapner.

Website to Collect, Share Information in Real Time with Parents, Clinicians

Trial data will be collected and shared in real time with parents and clinicians via the website, where expectant parents undergoing testing can learn how microarray works and what it looks for; parents of a child with a variance can find information about their baby's variance and connect with other parents of babies with the same variance; and physicians, genetic counselors, and other clinicians can input and research real-time information on the clinical impact of the variance.

"We will link genetic anomalies with structural abnormalitiesconnecting the genotype (the genetics, or errors) with the phenotype (what you see)," said Dr. Wapner. "This will help us to better understand the basis of birth defectsthings that run together, what genes to look for, and so on."

Software to better categorize ultrasound findings and relate them to the phenotype is provided by a genetics software-as-a-service company called Cartagenia, a collaborator on this work. As medical science continues to advance, Dr. Wapner and his colleagues hope and expect that this data pool (and web tracking system) will continue to improve genetic surveillance.

A web-based portal designed and hosted by David Ledbetter, PhD, and W. Andrew Faucett, MS, collaborators at Geisinger Health System in Danville, Pa., enables secure two-way communication with patients. This allows researchers to conduct surveys about patients' attitudes and opinions about testing; it can also help them to understand how the patients dealt with learning that their child has a genetic variance.

More About Microarray

Microarray requires fetal cells obtained through an invasive procedure (offered to high-risk pregnant women), such as amniocentesis, in which fetal cells are taken from the amniotic fluid, or chorionic villus sampling, in which cells are taken from the placenta. Pregnant women are deemed high risk if they have advanced maternal age (age 35 or older) or if their fetuses are shown through early screening to be at increased risk for Down syndrome, to have structural abnormalities (as seen with ultrasound), or to have indications of other problems. Parents deciding whether to undergo these tests must weigh a number of factors, including their individual risk of fetal abnormalities, possible procedure-induced miscarriage, and the consequences of having an affected child.

Wendy Chung, MD, PhD, associate professor of pediatrics (in medicine) at Columbia University Medical Center and director of clinical genetics at NewYork-Presbyterian/Columbia, is supervising the evaluation of the children.

The data are being housed at the George Washington University data center. Researchers at the University of Pennsylvania are leading the counseling and psycho-social portions of the study.


Contact: Elizabeth Streich
Columbia University Medical Center

Related biology news :

1. Ultrasound patch heals venous ulcers in human trial
2. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
3. New sickle cell anemia therapy advances to Phase II clinical trials
4. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
5. Intermountain Medical Center reseachers develop new 3-D technology to treat atrial fibrillation
6. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
7. Ecology, economy and management of an agro-industrial Amazon frontier
8. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
9. A trial to find out the effectiveness of biocides against Vespa velutina
10. Sea level rise: Jeopardy for terrestrial biodiversity on islands
11. Mummy CT scans show preindustrial hunter gatherers had clogged arteries
Post Your Comments:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
(Date:11/24/2015)... ... 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for production, ... to serve as Chief Operating Officer. , Having joined InSphero in November ... and was promoted to Head of InSphero Diagnostics in 2014. There she has ...
Breaking Biology Technology: